Xarelto Dangerous After TAVR, Halted Trial Suggests

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$650 Annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

Xarelto Dangerous After TAVR, Halted Trial Suggests

Posted: 10/09/2018
Author:
Crtonline.org
2018 News Articles

Excess in thrombotic events and death vs. DAPT in GALILEO trial

The GALILEO trial of rivaroxaban (Xarelto) therapy after transcatheter aortic valve replacement (TAVR) has been stopped early after a preliminary analysis suggested harm, Bayer announced.

Most Viewed Pages

Exercise Can Change Your Mind: Physical Activity’s CVD Benefits Linked to Stress-Related Neural Pathways

Live Case | Broadcasting from Tucson Medical Center | Tucson, AZ

Live Case | Broadcasting from Tucson Medical Center | Tucson, AZ

Abiomed’s Updated Instructions for Certain Impella Pumps Identified as Class I Action: FDA

Live Case Broadcasting from MedStar Washington Hospital Center | Washington, DC

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

Xarelto Dangerous After TAVR, Halted Trial Suggests

Excess in thrombotic events and death vs. DAPT in GALILEO trial

Most Viewed Pages

Explore the Site

Stay Connected